Different Injection Speed on Local Anaesthetic Spread of ESPB
Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Apr 13, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how the speed of injecting local anesthetic affects its spread in a procedure called the erector spinae plane block (ESPB). This block is used to numb an area during a procedure for lung nodules. The researchers want to find out if injecting the anesthetic quickly (in 30 seconds) makes it work differently compared to a slower injection (in 180 seconds).
To be eligible for this trial, participants need to be between 18 and 80 years old, scheduled for a CT-guided lung nodule localization, and have a body mass index (BMI) between 18 and 30. They must also be healthy enough for the procedure, with certain medical classifications. However, people with allergies to the anesthetic, a history of opioid abuse, or specific medical conditions may not qualify. If you join the trial, you can expect to help researchers learn more about the best way to deliver anesthesia to improve patient care during these types of procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients scheduled for CT-guided lung nodule localization under local anesthesia will be selected
- • 1. aged 18-80 years
- • 2. BMI 18-30 kg/m²
- • 3. ASA classification I-III
- Exclusion Criteria:
- • 1. Allergy to the study drug or to local anesthetics
- • 2. History of opioid abuse
- • 3. Previous infection at the ESPB or PVB puncture site
- • 4. Peripheral neuropathy
- • 5. Dysfunction of blood coagulation
About Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Trial Officials
Tao Shan
Study Chair
Nanjing First Hospital, Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported